The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jan. 03, 2023
Filed:
Mar. 23, 2022
Applicant:
Nanjing Zhengxiang Pharmaceuticals Co., Ltd., Nanjing, CN;
Inventor:
Xiaolin Hao, Foster City, CA (US);
Assignee:
NANJING ZHENGXIANG PHARMACEUTICALS CO., LTD., Nanjing, CN;
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07D 471/04 (2006.01); C07D 491/107 (2006.01); C07D 417/10 (2006.01); C07D 498/08 (2006.01); C07D 519/00 (2006.01); A61P 37/06 (2006.01); A61P 35/00 (2006.01); A61P 25/28 (2006.01); A61K 31/437 (2006.01); A61K 31/5377 (2006.01); A61K 31/5386 (2006.01); C07F 9/6558 (2006.01);
U.S. Cl.
CPC ...
C07D 471/04 (2013.01); A61P 35/00 (2018.01); A61P 37/06 (2018.01); C07D 417/10 (2013.01); C07D 491/107 (2013.01); C07D 498/08 (2013.01); C07D 519/00 (2013.01); C07F 9/65583 (2013.01); C07F 9/65586 (2013.01);
Abstract
The present disclosure provides selective phosphoinositide 3-kinase gamma inhibitors of Formula (I) including (I-a), (I-b), (I-c), and (I-d), or pharmaceutically acceptable salts thereof. These compounds are useful for the treatment of conditions mediated by one or more PI3K isoforms, such as PI3K gamma (PI3Kγ). The present disclosure further provides methods of inhibiting phosphoinositide 3-kinase gamma using these compounds for treatment of disorders related to phosphatidylinositol 3-kinase gamma activity.